Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 195 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Knee Osteoarthritis (Knee OA) Clear all
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

NCT03291470
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 8, 2026, 4:23 AM EDT
Enrolling by invitation Phase 4 Interventional

Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty

NCT07219888
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
oral suzetrigine, oral Oxycodone
Drug
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 89 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 8, 2026, 4:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Not applicable Interventional

fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA

NCT01040754
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Acupuncture
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

NCT02336698
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Costa Mesa, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Not applicable Interventional Results available

Physical Activity Pathway for Patients With Osteoarthritis in Primary Care (OA-PCP)

NCT03780400
View directory record Official record
Conditions
Osteoarthritis
Interventions
Osteoarthritis Physical Activity Care Pathway
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

HKT-500-US12 In Adult Patients With OA Knee Pain

NCT00647231
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
HKT-500 Topical Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Teriparatide as a Chondroregenerative Therapy in OA

NCT03072147
View directory record Official record
Conditions
Knee Osteoarthritis, Cartilage Degeneration
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
Christopher Ritchlin
Other
Eligibility
40 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 1 Interventional

Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA

NCT02790723
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
sc-rAAV2.5IL-1Ra
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 8, 2026, 4:23 AM EDT
Terminated Not applicable Interventional Results available

Optimization of Synvisc-One for Knee OA

NCT02029703
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Synvisc-One Injection, Sham Injection
Device · Other
Lead sponsor
Elaine Husni
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 8, 2026, 4:23 AM EDT
Recruiting Not applicable Interventional

Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain

NCT06872567
View directory record Official record
Conditions
Knee Osteoarthritis (Knee OA)
Interventions
genicular artery embolization, Corticosteroid Injection
Device · Drug
Lead sponsor
North American Science Associates Ltd.
Network
Eligibility
40 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 8, 2026, 4:23 AM EDT
Recruiting Phase 4 Interventional

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

NCT06245109
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Duloxetine, Celecoxib, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
41 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of NMES for Reducing Pain and Improving Functional Outcomes in Knee OA Patients

NCT03980964
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions
Active NMES
Device
Lead sponsor
CyMedica Orthopedics, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP, Normal Saline
Drug · Other
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
40 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 8, 2026, 4:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility Trial Using Imaging and Biochemical Technologies to Measure Knee Cartilage Composition in Acute ACL Injury

NCT02010125
View directory record Official record
Conditions
Acute Injury of Anterior Cruciate Ligament
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 8, 2026, 4:23 AM EDT
Active, not recruiting Not applicable Interventional

Impact of Different Exercise Programs on Knee OA

NCT05844124
View directory record Official record
Conditions
Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking)
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 8, 2026, 4:23 AM EDT
Active, not recruiting Phase 4 Interventional

Corticosteroid Meniscectomy Randomized Trial

NCT04641351
View directory record Official record
Conditions
Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Interventions
Zilretta Injectable Product or Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 2 Interventional

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

NCT05079035
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Interventions
TTAX03, Saline
Biological
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
35 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 8, 2026, 4:23 AM EDT
Active, not recruiting Not applicable Interventional

GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

NCT05818150
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Embosphere Microspheres, Corticosteroid injection
Device · Drug
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
21 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Not applicable Interventional

Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain

NCT06703970
View directory record Official record
Conditions
Knee Osteoarthritis (OA)
Interventions
Corticosteroid Injection, Platelet Rich Plasma Joint Injection
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
21 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

NCT02762370
View directory record Official record
Conditions
Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Interventions
FX006 32 mg, TCA IR 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
Anaheim, California • El Cajon, California • North Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 8, 2026, 4:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 8, 2026, 4:23 AM EDT
Terminated Not applicable Interventional

Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study

NCT03898388
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Bone Marrow Concentrate treatment
Procedure
Lead sponsor
Regenexx, LLC
Industry
Eligibility
35 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Des Moines, Iowa • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 8, 2026, 4:23 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of AposTherapy® in Knee OA

NCT03153956
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Calibrated AposTherapy®, Non-Calibrated Sham Apos Therapy Device
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
45 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 8, 2026, 4:23 AM EDT